Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligopeptide-10 is a synthetic bioactive peptide consisting of 15 amino acids with the sequence Phe-Ala-Lys-Ala-Leu-Lys-Ala-Leu-Leu-Lys-Ala-Leu-Lys-Ala-Leu. It is primarily utilized as an antimicrobial agent in topical cosmetic formulations for the treatment of acne. The peptide exhibits potent activity against Gram-positive bacteria, particularly *Cutibacterium acnes* (formerly *Propionibacterium acnes*), by binding to negatively charged lipoteichoic acids (LTA) on the bacterial cell wall. This binding induces osmotic imbalances and mechanical disruption of the cell membrane, resulting in bacterial cell death without the enzymatic pathways that typically lead to antibiotic resistance. It is often formulated alongside salicylic acid to provide synergistic anti-acne effects and is marketed under trade names such as Granactive Oligopeptide-10 for use in serums, cleansers, and patches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oligopeptide-10.